In today’s briefing:
- Potential Inclusions & Exclusions in KOSPI 200 Rebalance in May 2023
- WuXi AppTec (2359.HK/603259.CH) – Not the Time to Be Happy Even After a Positive Profit Alert
- Bio-Techne Corporation: Expansion RNAscope & Other Drivers
- Humana Inc.: Major Drivers
- Jazz Pharmaceuticals: Will It Be Able To Survive The Onslaught By Avadel’s Lumryz?
- Novartis AG: Major Drivers
Potential Inclusions & Exclusions in KOSPI 200 Rebalance in May 2023
- We discuss potential inclusions and exclusions of the upcoming KOSPI 200 rebalance in May 2023. With regards to the upcoming KOSPI 200 rebalance, we like the following long-short trading strategy.
- We would short a basket of potential exclusions from KOSPI 200 rebalance which would include the bottom 5% of KOSPI 200 index (10 stocks).
- We would go long a basket of potential inclusions in KOSPI 200 rebalance which include four stocks including Dentium, Jeju Air, Samyang Foods, and DGB Financial.
WuXi AppTec (2359.HK/603259.CH) – Not the Time to Be Happy Even After a Positive Profit Alert
- WuXi AppTec is facing how to keep high growth momentum under the high base of last year’s performance.If there’s no high growth point with certainty,high valuation is hard to sustain.
- The US wouldn’t stop tightening monetary policy until “it’s fully prepared”.Investors need to consider a situation that high interest rate environment is longer than expected,under which CXO remains in trouble.
- Market sentiment towards CXO has changed. We think CXO isn’t suitable for long-term hold but only for short-term trade in 2023. Buying low and selling high is a better strategy.
Bio-Techne Corporation: Expansion RNAscope & Other Drivers
- Bio-Techne delivered a disappointing result in the last quarter while failing to meet Wall Street expectations in terms of revenues as well as earnings.
- The company also noticed the strongest effects of decreasing biotech spending in Q2 in North America.
- The multiyear growth rates in North America remain in double digits and are consistent with its long-term objectives.
Humana Inc.: Major Drivers
- Humana had a mixed quarter as its revenues were below the analyst consensus estimate but it did manage an earnings beat.
- The company has fully deployed the value-based model in Virginia and North Carolina, covering over 760,000 members or 15% of Humana MA members by year’s end.
- Medicaid business maintained its strong performance despite lower-than-expected medical costs.
Jazz Pharmaceuticals: Will It Be Able To Survive The Onslaught By Avadel’s Lumryz?
- This is a special, one-time report on Jazz Pharmaceuticals, a company that is going through a significant challenge recently after its highest selling drug, Xyrem is on the verge of becoming obsolete with the arrival of Avadel’s Lumryz.
- In this report, we have carried out a fundamental analysis of the historical financial statements of the company.
- We also have a dedicated analysis of the company’s Environmental, Social, and Governance (ESG) risk scores in order to evaluate the sustainability risk.
Novartis AG: Major Drivers
- Novartis delivered a mixed set of results for the last quarter as it failed to meet the revenue expectations of Wall Street but managed an earnings beat.
- The management continued to invest in the organic business, pursued value-creating bolt-ons, and looked at the full range of M&A opportunities.
- To further extend their opportunities in gene therapy, they acquired PPY, their gene treatment for geographic atrophy in ophthalmology.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
